Targeting the NOX2/ROS/Mitochondria/NLRP3 Axis: Mechanistic Insights from XXLP in Ulcerative Colitis

Study Background and Research Question

Ulcerative colitis (UC) remains a chronic, relapsing inflammatory bowel disease with substantial morbidity worldwide. Its pathogenesis is complex, involving genetic predisposition, immune dysregulation, gut microbiome imbalance, and compromised intestinal barrier function. Conventional therapies, including aminosalicylates and corticosteroids, often fall short due to limited efficacy or adverse effects, highlighting the urgent need for novel therapeutic approaches. Xu Chunfu’s Modified Xianglian Pill (XXLP), rooted in traditional Chinese medicine and used clinically for centuries to treat symptoms akin to UC, has shown anecdotal efficacy but its underlying molecular mechanisms have remained obscure. The reference study sought to elucidate how XXLP mitigates colitis and to define its mechanistic targets in the context of the NOX2/ROS/mitochondria/NLRP3 axis (reference study).

Key Innovation from the Reference Study

The central innovation of this research lies in integrating proteomic profiling with molecular and microbiota analyses to unravel the multi-level action of XXLP in colitis. The study moves beyond symptom alleviation, demonstrating that XXLP directly modulates the NOX2/ROS/mitochondria/NLRP3 signaling cascade—a core axis linking oxidative stress, mitochondrial dysfunction, and inflammatory responses. By also characterizing shifts in gut microbial composition, the work positions XXLP as a dual-acting intervention, simultaneously targeting molecular inflammation and microbial dysbiosis.

Methods and Experimental Design Insights

The research employed a comprehensive experimental strategy:

• Chemical Composition Analysis: Ultra-performance liquid chromatography–ESI–MS/MS (UPLC-ESI-MS/MS) identified 373 distinct compounds in XXLP, providing a basis for subsequent mechanistic explorations.
• In Vivo Colitis Model: Mice were administered dextran sulfate sodium (DSS) to induce acute colitis. Therapeutic effects of XXLP were evaluated through body weight, disease activity index (DAI), colon length, and histopathology.
• Biochemical and Proteomic Validation: Inflammatory cytokines (IL-1β, IL-18, TNF-α, IL-6) were quantified by ELISA. Proteomic screening and molecular docking pinpointed NOX2 as a key target, which was further validated by qRT-PCR, Western blot, immunofluorescence, and transmission electron microscopy (TEM) in both mouse tissue and LPS-stimulated HT-29 cells.
• Microbiome Profiling: 16S rRNA gene sequencing assessed the impact of XXLP on gut microbial structure, focusing on both beneficial and pathogenic genera.

This multi-tiered approach allowed the authors to dissect both direct molecular and broader systemic effects of XXLP on the colitis model.

Protocol Parameters

• DSS-induced colitis: 2–3% DSS in drinking water for 7 days to establish acute colitis in mice; monitor body weight and DAI daily.
• XXLP administration: Oral dosing regimen typically initiated on day 1 of DSS exposure and continued for the duration of the experiment; dose titrated based on previous pharmacological studies.
• Inflammatory cytokine measurement: ELISA performed on serum and/or tissue lysates at the endpoint to quantify IL-1β, IL-18, TNF-α, and IL-6.
• Proteomics and molecular validation: Combine shotgun proteomics with targeted molecular assays (qRT-PCR, WB, IF) to confirm changes in NOX2 and associated axis components.
• Microbiome analysis: Extract DNA from fecal samples, amplify the V3–V4 region of the 16S rRNA gene, and sequence to determine genus-level abundance shifts.

Core Findings and Why They Matter

The study provides several pivotal findings:

• Symptom Improvement: XXLP significantly mitigated DSS-induced weight loss, reduced DAI scores, and preserved colon length, indicating robust anti-colitic efficacy (reference study).
• Suppression of Inflammation: Levels of pro-inflammatory cytokines (IL-1β, IL-18, TNF-α, IL-6) were markedly decreased in XXLP-treated mice, reflecting suppression of inflammatory signaling.
• NOX2/ROS/Mitochondria/NLRP3 Axis Regulation: Proteomic and molecular experiments confirmed that XXLP downregulated NOX2 and associated proteins, resulting in lower ROS production and reduced mitochondrial dysfunction. These changes blocked activation of the NLRP3 inflammasome, a known driver of mucosal inflammation and tissue injury.
• Gut Microbiota Remodeling: XXLP increased the relative abundance of beneficial genera (Muribaculaceae, Ruminococcaceae) and suppressed pathogenic Enterobacteriaceae. Correlation analysis further showed that specific bacteria are linked to NOX2-related protein expression and inflammatory severity.

Collectively, these findings clarify how XXLP exerts multi-modal anti-inflammatory actions and highlight the NOX2/ROS/mitochondria/NLRP3 axis as a central therapeutic node in UC.

Comparison with Existing Internal Articles

Several internal resources contextualize and reinforce the mechanistic insights from this study. For example, "ATP Sensing Transforms Inflammation Research" discusses the strategic value of high-sensitivity ATP quantification using firefly luciferase chemistry, emphasizing the importance of monitoring mitochondrial bioenergetics and immune signaling in inflammation models. This resonates with the present study’s focus on mitochondrial dysfunction and inflammasome activation as downstream consequences of NOX2-mediated oxidative stress.

Additionally, "XXLP Modulates NOX2/ROS/Mitochondria/NLRP3 Axis in Colitis" and "XXLP Targets NOX2/ROS/Mitochondria/NLRP3 Axis in Ulcerative Colitis" both substantiate the reference paper's findings, further supporting the role of this molecular pathway as a convergent mechanism for anti-inflammatory interventions. These studies collectively underscore the translational relevance of targeting mitochondrial and ROS-linked signaling in gastrointestinal disease models.

Limitations and Transferability

While the study provides strong evidence for XXLP’s multi-target mechanism in DSS-induced murine colitis, several caveats remain. The complexity of XXLP’s chemical makeup (over 370 compounds) challenges single-agent attribution, and the precise bioactive constituents responsible for NOX2 modulation have not been fully delineated. Additionally, while mouse models recapitulate many features of human UC, interspecies differences in immune responses and microbiota composition may affect transferability. Further studies are needed to validate these mechanisms in human tissues and to clarify potential drug–microbiome interactions in diverse patient populations.

Research Support Resources

For researchers aiming to investigate mitochondrial function, oxidative stress, or cellular energy metabolism in similar models, quantitative measurement of ATP is a critical assay parameter. The Luminescent ATP Detection Assay Kit (SKU: K2040) from APExBIO offers a sensitive, firefly luciferase-based approach for cellular ATP quantification. This kit streamlines sample lysis and provides stable luminescent signals, supporting workflows in energy metabolism assay and intracellular ATP level detection without harsh extraction steps. It is also compatible with downstream analyses, enabling integration into multi-omics or protein-focused studies as exemplified in the reference work.